用于癌症治疗的基于质粒DNA和病毒载体的疫苗。

Plasmid DNA and viral vector-based vaccines for the treatment of cancer.

作者信息

Anderson Richard J, Schneider Joerg

机构信息

Oxxon Therapeutics Ltd., 2nd Floor Florey House, 3 Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GP, UK.

出版信息

Vaccine. 2007 Sep 27;25 Suppl 2:B24-34. doi: 10.1016/j.vaccine.2007.05.030. Epub 2007 Jun 6.

DOI:10.1016/j.vaccine.2007.05.030

PMID:17698262

Abstract

Plasmid DNA and viral vector-based cancer vaccines have many inherent features that make them promising cancer vaccine candidates. This review focuses on the use of plasmid DNA and viral vector vaccines to deliver tumour-specific antigens to induce a tumour-specific immune response. Examples of different antigen delivery systems that have been tested in recent clinical trials are summarised and advantages and disadvantages of a number of delivery systems and approaches are discussed. Finally, an outlook on how plasmid DNA and viral vectors might be developed further as cancer vaccines is provided.

摘要

基于质粒DNA和病毒载体的癌症疫苗具有许多内在特性，使其成为很有前景的癌症疫苗候选物。本综述着重于利用质粒DNA和病毒载体疫苗递送肿瘤特异性抗原以诱导肿瘤特异性免疫反应。总结了近期临床试验中已测试的不同抗原递送系统的实例，并讨论了多种递送系统和方法的优缺点。最后，展望了质粒DNA和病毒载体作为癌症疫苗可能如何进一步发展。